$BCAX

Bicara Therapeutics Inc. (BCAX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. bcax-20260723 FALSE 0002023658 0002023658 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securitie

Cohlhepp Ryan (President and COO) sold 28,750 shares of Bicara Therapeutics Inc. (BCAX) at an average of $28.98 ($28.76–$30.35, $0.83M total) across 4 trades over 2026-07-08 to 2026-07-09 under a Rule 10b5-1 trading plan.

Hyep Ivan (Chief Financial Officer) sold 28,000 shares of Bicara Therapeutics Inc. (BCAX) at an average of $28.85 ($28.60–$30.31, $0.81M total) across 3 trades on 2026-07-08 under a Rule 10b5-1 trading plan.

Bicara Therapeutics (Nasdaq: BCAX) said it granted inducement stock options on July 1, 2026 to four new employees under its 2026 Inducement Plan. The options cover 191,425 shares at a $28.91 exercise price (Nasdaq close that day). Vesting is 25% after one year, then quarterly over 12 months, contingent on continued service.

Bicara Therapeutics CEO Claire Mazumdar sold shares after exercising 15,000 stock options on May 18, 2026, according to an SEC Form 4. The sale used a weighted-average price of $20.04. Her direct holdings fell about 4% to 362,152 shares, while she retained 146,107 options. The company is clinical-stage, with no revenue and a Q1 net loss of $56.2 million.

Bicara Therapeutics Inc. (BCAX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. bcax-20260609 FALSE 0002023658 0002023658 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securitie

Hyep Ivan (Chief Financial Officer) sold 9,200 shares of Bicara Therapeutics Inc. (BCAX) at $20.42 ($0.19M total) on 2026-05-21 under a Rule 10b5-1 trading plan.

Bicara Therapeutics announced that a combination of 1500mg weekly ficerafusp alfa and pembrolizumab demonstrated an estimated 31% overall survival at three years in patients with 1L R/M HPV-Negative HNSCC, approximately double the retrospective standard-of-care with pembrolizumab alone. The treatment showed deep, durable responses driven by TGF-β inhibition, with increasing complete response rates and deep response percentages across higher ficerafusp alfa dosages. The company is advancing with a Phase 3 study and planning a future maintenance regimen.

Bicara Therapeutics Inc.'s CEO, Claire Mazumdar, sold 15,000 shares of common stock at an average price around $20 per share and simultaneously exercised options to acquire 15,000 shares at $3.7898 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in February 2025. Following these moves, Mazumdar still directly holds 377,152 shares of common stock and retains options for an additional 146,107 shares, indicating continued significant equity exposure.

A Form 144 SEC filing by Bicara Therapeutics (NASDAQ: BCAX) details proposed insider sales through option exercises and several completed sales of common stock by a reporting person, Ryan Cohlhepp. The filing indicates proposed exercises of 4,500 and 8,000 shares, alongside five completed sales between January and March 2026, with their respective proceeds. This disclosure is a routine compliance notification regarding resale rules, noting no new material corporate action outside of these transactions.